KRN 5500 presents phase II: weak efficacy?

KRN 5500* has been tested in a phase II trial and the results were presented on april 20, 2010. More details will be presented in May in Athens, during the neuropathic pain congress. KRN 5500 is a spicamycin derivative and is available as a solution for intravenous (IV) administration.  

Press release DARA

105849349-motortion-Dreamstime-INP KRN 5500 presents phase II: weak efficacy?

  • “Correlation of Numeric Rating Scale (NRS), Neuropathic Pain Questionnaire (NPQ), and Keywords in Study for Treating Neuropathic Pain with KRN5500.” 

In addition, they state that will present:

  • “the correlation between post-treatment Numeric Rating Scale scores and Neuropathic Pain Questionnaire symptom scores. Baseline correlation was significant for electric (r=0.50), “sensitive to touch” (r=0.58), shooting (r=0.56) and tingling (r=0.55).

However, NPQ symptom scores did not correlate post-treatment with the statistically significant improvement seen in the NRS pain scores (combined symptoms). The largest median decrease in NRS scores in patients treated with KRN5500 was 29.3% while the median decrease for patients treated with placebo was zero.”

Some things are a bit odd here. Mostly a company presents first the outcome data instead of methodological issues. Furthermore, the placebo response on the NRS was zero, also very strange. The overall response of less than 30% seems also small, as we think in responses of at least 30-50%.  

Institute for Neuropathic Pain (INP), Netherlands

This site helps patients and treating physicians, neurologists, anesthesiologists and other pain specialists to find the best and most up to date research findings related to neuropathy and neuropathic pain and the treatment thereof.

In our center we are specialized in treating patients suffering from neuropathic pain and neuropathy following an Integrated Medicine concept. Part of our activities are within the field of consultation. We assist pharmaceutical companies in R&D strategies related to finding new drugs to treat neuropathic pain and neuropathy.

April 2010: Jan M. Keppel Hesselink, MD, PhD
KRN 5500 presents phase II: weak efficacy?

Statins side effects: myalgia and myopathy

 *= (6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-ß-L-manno-heptopyranosyl]amino-9H-purine)

Watch here our video’s about Neuropathy.

Propentofylline, a glia modulator
No new analgesics in 50 years
Pregabalin not effective in HIV neuropathy16


Wat kunnen wij voor u betekenen?

Wat kunnen wij voor u betekenen?

Ik ga akkoord met de privacyverklaring*